

Workshop on Clinical Outcome Assessments (COAs) in Cancer Clinical Trials(old)

Workshop on Clinical Outcome Assessments (COAs) in Cancer Clinical Trials

April 26, 2016

Sheraton Silver Spring Hotel

8777 Georgia Avenue

Silver Spring, MD 20910

Overview

This public workshop is co-sponsored by the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) and the Critical Path Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium. The workshop will include speakers and panelists from FDA, European Medicines Agency, health technology assessment bodies, domestic payers, academia, the medical product industry, and patient advocacy groups.

The purpose of the workshop is to provide a forum for collaborative multidisciplinary discussion aimed at gaining consensus on best practices for the use of PRO measures in oncology drug development. A broad array of international stakeholders will explore the utility of information derived from existing PRO measures with the overall goal of identifying potential ways to enhance stakeholder alignment around the strategic use of PRO measures to support oncology drug development and evaluation and better inform reimbursement and treatment decisions.

For more information or to register, please contact [Theresa Hall](#).